Table 2.
Univariate analysis of factors associated with mortality among HIV-infected adults on antiretroviral therapy
| Univariable Results (n = 23890) | ||||||||
|---|---|---|---|---|---|---|---|---|
| 6 months | 12 months | 24 months | 36 months | |||||
| OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | |
| Gender | ||||||||
| Male | 1.77 (1.49–2.09) | < 0.001 | 1.73 (1.49–2.01) | < 0.001 | 1.67 (1.47–1.91) | < 0.001 | 1.68 (1.48–1.91) | < 0.001 |
| Female | Ref | Ref | Ref | Ref | ||||
| Age groups | ||||||||
| 20–35 | Ref | Ref | Ref | Ref | ||||
| 36–50 | 1.14 (0.95–1.36) | 0.162 | 1.23 (1.04–1.44) | 0.013 | 1.18 (1.02–1.36) | 0.024 | 1.16 (1.02–1.33) | 0.028 |
| 51+ | 1.41 (1.08–1.85) | 0.012 | 1.57 (1.25–1.99) | < 0.001 | 1.58 (1.29–1.94) | < 0.001 | 1.57 (1.29–1.91) | < 0.001 |
| Marital Status | ||||||||
| Single | 1.3 (1.01–1.68) | 0.043 | 1.35 (1.08–1.68) | 0.008 | 1.36 (1.13–1.64) | 0.002 | 1.34 (1.12–1.6) | < 0.001 |
| Divorced | 1.96 (1.58–2.43) | < 0.001 | 1.80 (1.49–2.18) | < 0.001 | 1.76 (1.49–2.08) | < 0.001 | 1.79 (1.53–2.11) | < 0.001 |
| Married | Ref | Ref | Ref | Ref | ||||
| Widowed | 1.34 (1.01–1.77) | 0.043 | 1.19 (0.92–1.53) | 0.186 | 1.29 (1.04–1.60) | 0.023 | 1.3 (1.05–1.61) | 0.014 |
| BMI | ||||||||
| < 18.5 | 1.96 (1.56–2.47) | < 0.001 | 1.85 (1.52–2.26) | < 0.001 | 1.82 (1.53–2.17) | < 0.001 | 1.79 (1.52–2.11) | < 0.001 |
| 18.5–24.9 | Ref | Ref | Ref | Ref | ||||
| 25–29.9 | 0.50 (0.32–0.78) | 0.002 | 0.54 (0.36–0.81) | 0.003 | 0.57 (0.41–0.8) | 0.001 | 1.10 (0.63–1.94) | 0.001 |
| 30+ | 0.37 (0.17–0.81) | 0.013 | 0.45 (0.24–0.85) | 0.013 | 0.53 (0.31–0.91) | 0.02 | 0.54 (0.34–0.88) | 0.013 |
| CD4 | ||||||||
| 0–250 | 2.35 (0.39–14.22) | 0.354 | 2.23 (0.45–11.11) | 0.329 | 1.42 (0.48–4.23) | 0.528 | 1.52 (0.51–4.49) | 0.453 |
| 251–500 | 0.91 (0.14–5.83) | 0.923 | 0.94 (0.18–4.77) | 0.938 | 0.57 (0.18–1.74) | 0.320 | 0.66 (0.22–2.00) | 0.460 |
| Above 500 | Ref | Ref | Ref | Ref | ||||
| Regimen Started | ||||||||
| D4T-based | Ref | Ref | Ref | Ref | ||||
| ABC-based | 0.77 (0.38–1.57) | 0.476 | 0.59 (0.29–1.2) | 0.146 | 0.50 (0.26–0.98) | 0.042 | 0.44 (0.23–0.86) | 0.016 |
| AZT-based | 0.82 (0.65–1.02) | 0.076 | 0.80 (0.66–0.98) | 0.147 | 0.73 (0.61–0.87) | < 0.001 | 0.69 (0.58–0.82) | < 0.001 |
| TDF-based | 0.50 (0.39–0.63) | < 0.001 | 0.50 (0.40–0.61) | 0.148 | 0.49 (0.41–0.59) | < 0.001 | 0.48 (0.40–0.57) | < 0.001 |
| WHO Stage clinical stage at ART initiation | ||||||||
| Stage I | Ref | Ref | Ref | Ref | ||||
| Stage II | 1.56 (1.03–2.37) | 0.036 | 1.57 (1.07–2.30) | 0.02 | 1.56 (1.11–2.18) | 0.01 | 1.50 (1.09–2.06) | 0.012 |
| Stage III | 3.37 (2.23–5.10) | < 0.001 | 3.32 (2.29–4.82) | < 0.001 | 3.10 (2.26–4.25) | < 0.001 | 2.84 (2.11–3.83) | < 0.001 |
| Stage IV | 8.18 (5.38–12.44) | < 0.001 | 7.68 (5.27–11.20) | < 0.001 | 7.25 (5.23–10.04) | < 0.001 | 6.41 (4.68–8.78) | < 0.001 |